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Abstract
BACKGROUND: Th1 cytokines exert pleiotropic effects in Hashimoto's thyroiditis.
Previous studies reported a downregulation of thyroperoxidase and dual oxidase
(DUOX) protein and mRNA expression in thyroid cells treated with Th1 cytokines.
Although this effect is partially mediated by intracellular reactive oxygen species
(ROS) and reactive nitrogen species, the nature and the source of the ROS
involved are currently unknown. The aim of this study was to examine further
the nature and source of the ROS produced in response to Th1 cytokines.
METHODS: Two rat thyroid cell lines (PCCL3 and FRTL-5) and human thyrocytes
were incubated with Th1 cytokines (interleukin [IL]-1α and interferon-γ) in the
presence or absence of the Th2 cytokine IL-4, the nitric oxide synthase inhibitor
N-nitroso-L-arginine methyl ester (L-NAME), or the synthetic antioxidant N-
acetylcysteine. The nature and source of the intracellular and extracellular ROS
produced were determined. RESULTS: A rapid increase in i...
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Differential Regulation of the Production of Reactive
Oxygen Species in Th1 Cytokine–Treated Thyroid Cells
Ides M. Colin,1,* Sylvie Poncin,1,* Philippe Leveˆque,2 Bernard Gallez,2 and Anne-Catherine Ge´rard1
Background: Th1 cytokines exert pleiotropic effects in Hashimoto’s thyroiditis. Previous studies reported a
downregulation of thyroperoxidase and dual oxidase (DUOX) protein and mRNA expression in thyroid cells
treated with Th1 cytokines. Although this effect is partially mediated by intracellular reactive oxygen species
(ROS) and reactive nitrogen species, the nature and the source of the ROS involved are currently unknown. The
aim of this study was to examine further the nature and source of the ROS produced in response to Th1
cytokines.
Methods: Two rat thyroid cell lines (PCCL3 and FRTL-5) and human thyrocytes were incubated with Th1
cytokines (interleukin [IL]-1a and interferon-c) in the presence or absence of the Th2 cytokine IL-4, the
nitric oxide synthase inhibitor N-nitroso-L-arginine methyl ester (L-NAME), or the synthetic antioxidant
N-acetylcysteine. The nature and source of the intracellular and extracellular ROS produced were determined.
Results: A rapid increase in intracellular ROS was observed in cells incubated with Th1 cytokines. This increase
was not caused by extracellular hydrogen peroxide (H2O2) produced by DUOX because both DUOX expression
and extracellular H2O2 synthesis were decreased by Th1 cytokines. Confocal colocalization experiments showed
that the Th1 cytokine–triggered ROS were not produced from mitochondria. Electron paramagnetic resonance
investigations of PCCL3 cells indicated that the highly reactive hydroxyl radical was not involved in the
response to Th1 cytokines. NOX2 mRNA expression was significantly increased in PCCL3 cells incubated with
Th1 cytokines, as was the expression of the protein in the thyroid of Hashimoto’s thyroiditis patients. NOX4
expression was by contrast unaffected. These results suggest that at least superoxide could be produced after
exposure of thyroid cells to Th1 cytokines. The effects of L-NAME and IL-4, both of which partially or totally
reverse Th1 cytokine–induced effects, on ROS release were also analyzed. L-NAME and IL-4 significantly
reduced the Th1 cytokine–induced surge of intracellular ROS in PCCL3 and human thyroid cells.
Conclusion: The data presented here reinforce the idea that ROS, other than extracellular H2O2 produced by
DUOX, are released from NOX2 after exposure of thyroid cells to Th1 cytokines. ROS/reactive nitrogen species
act as important, but as further explained, not exclusive intracellular mediators of Th1 cytokine–induced effects
in thyroid cells.
Introduction
Th1 cytokines are involved in the local inflammatoryreaction that occurs in Hashimoto’s thyroiditis (HT) and
play a key role in the outcome of the disease (1–5). HT often
results in hypothyroidism, but evidence accumulated over
the last few decades indicates that cell death is not the sole
cause of this outcome. In addition to their pathogenic roles
in cellular immune responses and apoptosis, Th1 cytokines
can directly alter the function of thyrocytes. For example,
interleukin-1a (IL-1a), tumor necrosis factor-a, and interferon-c
(IFNc) inhibit iodide uptake, sodium-iodide symporter (NIS)
mRNA expression (6,7), and thyroid hormone (TH) release
from human thyrocytes (8). IL-1a and IFNc also downregulate
dual oxidase (DUOX), thyroperoxidase (TPO), and thyro-
globulin (Tg) expression in human thyrocytes, without af-
fecting cell viability (9–11).
In addition to reactive nitrogen species (RNS) such as nitric
oxide (NO) (12–14), reactive oxygen species (ROS) are also
thought to act as intracellular mediators of Th1 cytokine–
induced effects in thyroid cells (11,15). This must be distin-
guished from the physiological role exerted by ROS in thyroid
epithelial cells. For instance, hydrogen peroxide (H2O2) is
physiologically produced in the thyroid gland and is involved
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in TH biosynthesis (16–18). H2O2 is therefore part of the
physiological oxidative load, which is not the cause of cell
injury, but instead associated with cellular events responsible
for normal thyroid epithelial cell function (16,19). ROS are also
involved in the hypoxia-inducible factor–mediated vascular
endothelial growth factor pathway that is activated in thyro-
cytes in response to iodine shortage, which makes the endo-
thelial compartment closely related to epithelial cells within
the angiofollicular units (16,20,21). Other ROS, including hy-
droxyl radical (OH), anion superoxide (O2
- ), peroxynitrite
(ONOO - ), and iodocompounds, are more reactive and
sometimes toxic, as demonstrated in animal models of iodine-
induced thyroid involution and in the nonobese diabetic
mouse model of spontaneous autoimmune destructive thy-
roiditis (22–26).
A link between Th1 cytokine exposure and production of
ROS was recently reported in rat PCCL3 thyroid cells (11).
This observation raised questions about the nature and source
of ROS produced after Th1 cytokine exposure; while Th1 cy-
tokines downregulate DUOX expression, and therefore the
production of extracellular H2O2 (9–11), they trigger at the
same time a surge of intracellular ROS production (11). Be-
cause DUOX is downregulated by Th1 cytokines, and as H2O2
is either consumed during TH synthesis or readily detoxified
by the numerous potent antioxidant systems present in the
thyroid (16), we propose that ROS other than extracellular
H2O2 are produced in response to Th1 cytokines by NADPH
oxidases (NOXs) other than DUOX.
The aims of this study were to gain further insights into the
nature of the ROS produced in cells exposed to Th1 cytokines
and to identify which NOXs are induced under these conditions.
The effects of N-nitroso-L-arginine methyl ester (L-NAME), a
nitric oxide synthase (NOS) inhibitor, and of interleukin-4 (IL-4),
a prototype of Th2 cytokines, on ROS production were also
examined and compared with the known inhibitory effect of
the potent antioxidant N-acetylcysteine (NAC).
Materials and Methods
Cell cultures
The rat thyroid follicular PCCL3 cell line (27) was a gift from
Dr. F. Miot (Universite´ Libre de Bruxelles, Institut de Recherche
Interdisciplinaire en Biologie Humaine et Mole´culaire, Brus-
sels, Belgium). Cells were seeded into 6-well plates or multi-
chamber glass slides (Nunc International) and were cultured
in a humidified atmosphere of 5% CO2. They were grown to
80–90% confluence in Coon’s modified Ham’s F12 medium
(BRL-Gibco) supplemented with 5% newborn calf serum,
50 U/mL penicillin, 50lg/mL streptomycin, 2.5lg/mL fun-
gizone (BRL-Gibco), 1 mU/mL thyrotropin (TSH), 10lg/mL
insulin, and 5lg/mL transferrin (Sigma). A cytokine cocktail
comprising recombinant rat IL-1a (2 ng/mL; Chemicon Inter-
national) and recombinant rat IFNc (100 U/mL; Chemicon
International) was added for 3 additional days, with or without
1 mM NAC (Sigma), 2.5 mM L-NAME (Sigma), or 2 ng/mL
recombinant rat IL-4 (a gift from Dr. Vanderbruggen, Uni-
versite´ catholique de Louvain, The de Duve Institute, Brussels,
Belgium). NAC was added 2 hours before the cytokine cocktail.
As a control, NAC, L-NAME, and IL-4 were added to thyroid
cells in the absence of IL-1a and IFNc.
FRTL-5 cells that were used for measurement of extracel-
lular H2O2 were a gift from Dr. P. Kopp (Northwestern Uni-
versity, Chicago, IL). These cells were grown to 80–90%
confluence in Coon’s modified Ham’s F12 medium (Gibco)
supplemented with 5% newborn calf serum, 5 mU/mL TSH,
10lg/mL insulin, 5lg/mL transferrin, 10 ng/mL somatostatin,
10 ng/mL glycyl-L-histidyl-L-lysine-acetate, and 3.2 ng/mL
hydrocortisone (6H medium).
Human thyroid tissues were obtained from patients who
underwent thyroid surgery for benign multinodular goiters.
Tissues were obtained from the anatomopathology depart-
ment after patients provided informed consent. Thyrocytes
were isolated from the tissue samples as described previously
(28) and then seeded into 6-well plates (50 lg DNA per well)
or multichamber glass slides (7lg DNA per chamber). Thyro-
cytes were incubated in a humidified atmosphere of 5% CO2
and were cultured in modified Earle’s medium (without
phenol red) supplemented with 5% newborn calf serum,
50 U/mL penicillin, 50 lg/mL streptomycin, 2.5 lg/mL fun-
gizone, and 1 mU/mL TSH. After incubation for 1 week, cells
were exposed to cytokines in the presence or absence of NAC,
L-NAME, or IL-4 for an additional 3 days, as described for
PCCL3 cells. All experiments were repeated at least twice.
Unless otherwise stated, all reagents listed were purchased
from Sigma.
Human thyroid samples for immunohistochemistry
and reverse transcription polymerase chain reaction
Thyroid samples for immunohistochemistry were obtained
from five multinodular goiters and five HT thyroids selected
from a tissue bank of the pathology department. They were
fixed in formol (4%) and embedded in paraffin. Other samples
from 3 multinodular goiters and 2 HT thyroids were obtained
from surgical cases after patients gave their informed consent
and immediately frozen in liquid nitrogen, and thereafter
conserved at -80C until use for reverse transcription poly-
merase chain reaction (RT-PCR). HT patients had normal to
high normal TSH levels along with high levels of plasma
anti-TPO and anti-Tg antibodies. They were all treated with
thyroxine.
Measurement of ROS production and labeling
of mitochondria
Thyrocytes were incubated in multichamber glass slides in
the appropriate medium. To label mitochondria, thyroid cells
were washed with phosphate-buffered saline (PBS; pH 7.4)
and then incubated in Krebs–Ringer HEPES medium (KRH)
(pH 7.4) containing 250 nM MitoTracker dye (Molecular
Probes) at 37C for 30 minutes. To measure ROS production,
cells were washed with KRH, incubated in the appropriate
culture medium at 37C for 15 minutes, and then incubated in
KRH containing 25lM 2¢,7¢dichlorofluorescein diacetate
(DCFH-DA; Molecular Probes) at 37C for a further 30 minutes.
The excess dye was removed by two washes with PBS. Cells
were stained with Hoechst dye for 20 minutes and rinsed in
PBS. Cover slides were mounted in the fluorescent mounting
medium (DakoCytomation) for confocal microscopy.
Confocal microscopy and identification
of colocalized signals
Optically sectioned images were acquired using a Leica SP5
laser scanning confocal microscope and were analyzed using
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Leica Microsystems LAS AF software (v1.8.2). ROS produc-
tion was quantified by measuring the mean fluorescence
intensity of each cell. For colocalization analysis, the ‘‘colo-
calization’’ module of Imaris software (v6.1.2; Bitplane, Zur-
ich, Switzerland) was used (29). Briefly, this program analyzes
images of confocal sections acquired in two channels. Labels
were considered colocalized if they were positioned too close
in the tissue to be optically resolved. Each confocal section
consisted of an array of pixels, and a voxel was defined as a
prism in which the base is the pixel and the height is the
thickness of the confocal section. Imaris colocalization soft-
ware measures the intensity of each label in each voxel in the
entire confocal image. A pixel intensity threshold of 16 (on a
scale of 0–255) was used for each label, and voxel intensity
values above this threshold were considered to be higher than
the background intensity. When the intensity of both labels in
a voxel was higher than their respective thresholds, the labels
were considered colocalized. The Pearson coefficient was
used to estimate the degree of correlation between the inten-
sity values for the two labels in voxels showing colocalization.
The Pearson coefficient lies between +1 and -1; positive
values indicate a direct correlation, and values close to zero
indicate no correlation.
Measurement of hydroxyl radical by spin trapping
and electron paramagnetic resonance spectroscopy
These experiments were performed according to methods
previously published (30,31). PCCL3 cells at 80–90% conflu-
ence were seeded into a 6-well plate, incubated with or
without 2 ng/mL recombinant rat IL-1a and 100 U/mL IFNc
for 3 days, and then trypsinized and suspended in a final
volume of 0.4 ml. Cells were incubated with the spintrap 5-
diethoxyphosphoryl-5methyl-1-pyrroline-N-oxide (RadicalVi-
sion) at 37C for 1 minute and then with 12.5lM K3Fe(CN)6
(Merck) for further 5 minutes. Cells were then transferred into a
quartz flat cell (ER 160 FC-Q; Bru¨ker), and the quartz cell was
positioned in an X-band electron paramagnetic resonance
(EPR) Super High Q cylindrical resonator (ER4122SHQE,
10 mm diameter; Bru¨ker) with its flat side perpendicular to the
direction of the magnetic field. EPR spectra were measured at
room temperature using a Bru¨ker Elexys 540 spectrometer
(Bru¨ker) operating at 9.5 GHz. The magnetic field center was
347.63 mT with a Sweep Width of 20.0 mT (512 pts). The mi-
crowave power was 5 mW with a receiver gain of 60 dB. The
modulation frequency was 100 kHz, the modulation amplitude
was 0.1 mT, the conversion time was 20.48 milliseconds, and
the time constant was 81.92 milliseconds. Spectra were deter-
mined as the mean of 10 scans.
Detection of H2O2 in the culture medium
FRTL-5 cells were incubated for 4 hours in the KRH me-
dium supplemented with 0.1 mg/mL horseradish peroxidase
type II (Sigma) and 440lM homovanillic acid (Sigma). A
standard curve was generated by adding known concentra-
tions of H2O2 to the KRH medium containing horseradish
peroxidase and homovanilic acid. The fluorescence intensity
was measured at an excitation wavelength of 315 nm and an
emission wavelength of 415 nm. H2O2 concentrations were
estimated using the standard curve. H2O2 production was
calculated as nanograms of H2O2 per milliliter of the culture
medium.
Real-time RT-PCR
PCCL3 and human primary cells, as well as thyroid lysates,
were suspended in TriPure isolation reagent (Roche Diag-
nostics GmbH), and total RNA samples were prepared ac-
cording to the manufacturer’s protocol. Reverse transcription
was performed by incubating 2lg of RNA with 200 U of
Moloney Murine Leukemia Virus Reverse Transcriptase (In-
vitrogen) in a final volume of 20lL of the recommended
buffer containing 1lL RNasin (Promega), 0.5 mM dNTP
(Promega), 2 lM oligodT (Sigma), and 10 mM DTT. The re-
verse transcription reactions were performed overnight at
42C, and then the resulting cDNAs were diluted 1:5 in water.
For real-time PCR, 2lL of cDNAs was mixed with 500 nM
primers (Table 1) and SYBR Green reaction mix (BioRad) in a
final volume of 25 lL. Reactions were performed using an
iCycler PCR system (BioRad) with the following cycling
conditions: 95C for 1 minute, followed by 40 cycles of 95C
for 15 seconds, specific annealing temperature for 45 seconds,
and 81C for 15 seconds. Amplification levels were normal-
ized to that of b-actin.
Immunohistochemistry
Paraffin sections (5 lm) were used for Nox2 protein de-
tection. Sections were dewaxed, rehydrated, and pretreated
in a microwave oven in citrate buffer (0.01 M, pH 6) for 1
cycle of 3 minutes at 750 W and 3 cycles of 3.5 minutes at 350
W. Sections were then washed with PBS supplemented with
1% bovine serum albumin (PBS-BSA) and thereafter incu-
bated with normal goat serum (1/50 in PBS-BSA; Vector
Laboratories) for 30 minutes at room temperature. The rabbit
polyclonal anti-Nox2 antibody (Abcam) was then applied
overnight. After two washes in PBS-BSA, the secondary
biotinylated antibody was incubated for 60 minutes fol-
lowed by avidin–biotin–peroxidase complex for 30 minutes
Table 1. Forward and Reverse Primers and Annealing Temperatures Used
Target Primer forward Primer reverse
Annealing
temperature, C
Actin 5¢-CAT CCT GCG TCT GGA CCT-3¢ 5¢-AGG AGG AGC AAT GAT CTT GAT-3¢ 62
rNox2 5¢-GGC TGG TGC GGT TTT GGC GAT-3¢ 5¢-TTG GAC ACT GCG GGA CGC TT-3¢ 55
rNox4 5¢-TCG CGG ATC ACA GAA GGT C-3¢ 5¢-AGG CCC GGA ACA GTT GTG AAG AGA-3¢ 54.5
hNox2 5¢-TCA GGG CAC TGA GGG TAG GTC TG-3¢ 5¢-CCT GAG GTG CAG TGT GAA CAG GC-3¢ 59
hNox4 5¢-CCA AGC AGG AGA ACC AGG AGA TT-3¢ 5¢-AGG CCA GGA ACA GTT GTG AAG AGA-3¢ 54.5
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(ABC Perox kit; Vector Laboratories) at room temperature.
The peroxidase activity was revealed with DAB substrate
(Sigma).
Data analysis and statistics
The data were expressed as mean– SEM (n= 6) for all
in vitro experiments. Each experiment was repeated at least
twice. Statistical analyses were performed using an ANOVA
followed by the Tukey–Kramer Multiple Comparison Test
(GraphPad InStat), or an unpaired Student’s t-test. Differ-
ences were considered significant at p< 0.05.
Results
Th1 cytokines increase intracellular ROS
but decrease production of extracellular H2O2
Consistent with a previous report (11), ROS, which were
detected by DCFH-DA fluorescence, were observed as a
faint staining within the cytoplasm of both rat PCCL3 (Fig.
1A-i) and human thyroid cells (data not shown). After treat-
ment of cells with Th1 cytokines, the staining was greatly
enhanced (Fig. 1A-ii). The fluorescent signal in Th1 cytokine–
treated cells was eightfold higher than that in nontreated cells
(Fig. 1B).
DUOX2, which is responsible for H2O2 production, is one
of the main sources of ROS in thyroid epithelial cells (32).
However, since previous studies have repeatedly demon-
strated that Th1 cytokines decrease DUOX expression in
thyrocytes (9–11,33), ROS detected in Th1 cytokine–treated
cells were thought not to be attributable to DUOX-produced
H2O2. To verify this hypothesis, FRTL-5 cells were treated
with or without IL-1a and IFNc, and then extracellular H2O2
levels were measured. Compared with control cells, the
level of extracellular H2O2 was significantly decreased in
cytokine-treated cells (Fig. 1C). Taken together, these data
indicate that Th1 cytokines increase intracellular ROS pro-
duction, while decreasing H2O2 release from thyroid epi-
thelial cells.
Th1 cytokine–induced ROS are not hydroxyl radicals
and are not produced by mitochondria, but are
associated with increased NOX2 mRNA expression
To identify the nature of the ROS produced by thyroid cells
in response to Th1 cytokines, OH levels were analyzed by
EPR. Although OH was detected at low levels in PCCL3 cells,
production of this species was not affected by exposure of
cells to IL-1a and IFNc (Fig. 2A), indicating that OH is
probably not involved in the response of thyroid epithelial
cells to Th1 cytokines.
ROS are physiologically released byproducts of biological
reactions that originate from various organelles, including
mitochondria, the endoplasmic reticulum, and peroxisomes
(34–40). Although the respiratory chain involved in ATP
generation by mitochondria is an important source of ROS
(41,42), superimposition of confocal microscopy images of
ROS and mitochondria in PCCL3 cells revealed no overlap
(Fig. 2B). Calculation of the Pearson coefficient confirmed that
the site of ROS production in these cells was not colocalizing
with mitochondria (Fig. 2C), indicating that Th1 cytokine–
induced ROS do not originate primarily from mitochondria.
Bearing in mind that NOXs other than DUOX may produce
ROS in Th1 cytokine–treated cells, other alternatives were
explored. NOX4 mRNA was detected in both PCCL3 (Fig. 3A)
and human cells (data not shown), but the expression levels
were unaffected by exposure of cells to Th1 cytokines. Ex-
pression of NOX2 mRNA, which encodes the prototype of
NOXs originally identified in phagocytes (43), was strongly
increased in Th1 cytokine–treated PCCL3 cells (Fig. 3B),
suggesting that NOX2 is a possible source of ROS in Th1
cytokine–treated thyroid cells.
NOX2 mRNA and protein expression
is increased in HT
To further explore the hypothesis that NOX2 may be one
source of ROS in HT thyroids, we investigated NOX2 mRNA
and protein expression in HT thyroids as compared with
multinodular goiters as a nonautoimmune control. NOX2
FIG. 1. Th1 cytokines increase in-
tracellular ROS and decrease extra-
cellular H2O2. (A) ROS production
was visualized using a DCFH-DA
probe (green fluorescence) in control
PCCL3 cells (i) and in PCCL3 cells
treated with 2 ng/mL IL-1a and
100 U/mL IFNc (ii). Scale bars:
10lm. (B) The DCFH-DA fluores-
cence was quantified by measuring
the mean fluorescence of each cell.
Data were calculated as fold chan-
ges compared with controls and are
represented as the mean– SEM of
n= 10 cells. *p< 0.05 vs. control. (C)
Levels of H2O2 in the culture me-
dium of conditioned FRTL-5 cells.
Data are represented as the mean–
SEM of n= 6 individual wells.
*p< 0.05 vs. control. DCFH-DA,
2¢,7¢dichlorofluorescein diacetate;
IFNc, interferon-c; IL-1a, interleukin-
1a; ROS, reactive oxygen species.
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mRNA expression in HT was twofold higher than that in
multinodular goiters (Fig. 4A). Nevertheless, because of the
low number of HT cases (n = 2), the difference was not sig-
nificant. We then analyzed NOX2 protein expression by
immunohistochemistry on tissues obtained from a greater
number of cases. In the multinodular goiters (Fig. 4B, D),
NOX2 protein expression was detected in the cytoplasm of
some cells. In HT thyroids (Fig. 4C, E), in addition to a high
level of expression in the inflammatory infiltrate (not
shown), a strong staining for NOX2 was visible in the vast
majority of thyrocytes. These results are in line with the
in vitro results and reinforce the concept of a role of NOX2 in
thyroid cells exposed to Th1 cytokine–driven autoimmune
processes.
FIG. 3. Expression of NOX4 mRNA (A) is unaffected, while that of NOX2 mRNA (B) is increased in Th1 cytokine–treated
PCCL3 cells. Expression levels of each mRNA were analyzed by real-time PCR. Data are represented as the mean– SEM of
n = 5 repeats and are normalized to b-actin expression. *p < 0.05 vs. control. PCR, polymerase chain reaction.
FIG. 2. The hydroxyl radical (OH) is not
released, and intracellular ROS do not colo-
calize with mitochondria in Th1 cytokine–
treated PCCL3 cells. (A) Levels of the hy-
droxyl radical (OH) in PCCL3 cells detected
by EPR. (B) Confocal microscopy analysis of
the ROS signal in control cells (i) and cells
treated with 2 ng/mL IL-1a and 100 U/mL
IFNc (ii), detected using a DCFH-DA probe
(green fluorescence). Mitochondria were la-
beled using MitoTracker dye (red fluores-
cence). Scale bar: 10lm. (C) The Pearson
coefficient was calculated to determine the
degree of correlation between the intensities
of the labels shown in panel A. No colocali-
zation between ROS production and mito-
chondria was observed (Pearson coefficient
close to zero). EPR, electron paramagnetic
resonance.
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The levels of intracellular ROS are decreased
in Th1 cytokine–treated thyroid cells co-incubated
with L-NAME or IL-4
L-NAME and IL-4 attenuate the effects of Th1 cytokines, at
least partially (9,10); therefore, we investigated the effects
of these compounds on ROS induction in thyroid cells. NAC,
which completely blocks ROS production in cells co-
incubated with Th1 cytokines (11), was used as a positive con-
trol. As reported previously (11), compared with control PCCL3
(Figs. 5A and 6A) and human cells (Fig. 6B), intracellular ROS
levels were significantly higher in Th1 cytokine–treated
PCCL3 (Figs. 5B and 6A) and human cells (Fig. 6B). Compared
with control cells, exposure to L-NAME alone somewhat in-
creased the ROS signal in PCCL3 cells (Figs. 5C and 6A), but
decreased the ROS signal in human cells (Fig. 6B). L-NAME
significantly reduced the Th1 cytokine–induced increase in
ROS in both PCCL3 (Figs. 5D and 6A) and human cells (Fig.
6B). Compared with control cells, exposure to IL-4 alone
somewhat increased the ROS signal in PCCL3 cells (Figs. 5E
and 6A), but did not affect the ROS signal in human thyroid
cells (Fig. 6B). IL-4 significantly reduced the Th1 cytokine–
induced increase in ROS in both PCCL3 (Figs. 5F and 6A) and
human cells (Fig. 6B). Compared with control cells, exposure to
NAC alone strongly decreased the ROS signal in PCCL3 (Figs.
5G and 6A) and in human thyroid cells (Fig. 6B). NAC signifi-
cantly decreased the ROS signal in Th1 cytokine–treated PCCL3
cells to a level close to that observed in control cells (Figs. 5H
and 6A), whereas in Th1 cytokine–treated human cells (Fig. 6B),
the ROS signal was even slightly below to that in control cells.
Together with previous reports that described a partial or
total restoration of DUOX and TPO expression in Th1 cytokine–
treated thyroid cells co-incubated with either L-NAME or IL-4
(9,10), the data presented here indicate that ROS act as impor-
tant, but as discussed below, not exclusive intracellular medi-
ators of Th1 cytokine–induced effects in thyroid cells.
FIG. 4. Expression of NOX2
mRNA (A) is increased in
the thyroid of HT patients,
but the difference was not
significant because of the low
number of cases (n = 2). Ex-
pression levels of each mRNA
were analyzed by real-time
PCR. Data are represented as
the mean– SEM of n = 3 (con-
trols) or n = 2 (HT) and are
normalized to b-actin expres-
sion. The expression of NOX2
protein was increased in HT
thyroids (C, E), as compared
with multinodular goiters (B,
D). HT, Hashimoto’s thy-
roiditis.
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Discussion
HT and Graves’ disease are at either end of the spectrum of
autoimmune thyroid diseases (44,45). Individuals with HT,
which is predominantly a Th1 cytokine–driven disease, often
experience hypothyroidism caused by cell death and/or im-
pairment of thyroid cell function (1–5). In addition to their role
in the regulation of immune cells, Th1 cytokines can act di-
rectly on thyrocytes. For example, Th1 cytokines increase the
production of MHC class I antigens, MHC class II antigens,
and ICAM-1 by thyrocytes (44,46), and also induce cytotox-
icity, as illustrated by the Th1 cytokine–induced production of
lactate dehydrogenase by human thyrocytes (14). In addition,
IL-1b and IFNc induce Fas-activated apoptosis (47,48) and
inhibit thyroid cell growth (49). Furthermore, Th1 cytokines
directly interfere with thyroid cell functions without affecting
cell viability, suggesting that cell death is not the sole mech-
anism leading to hypothyroidism in HT. IL-1a, tumor necrosis
factor-a, and high doses of IFNc inhibit iodide uptake, NIS
mRNA expression (6,7), iodine incorporation, and hormone
release from human thyrocytes (8). IFNa and IFNb inhibit
iodide uptake and organification, as well as thyroxine release
(48,50). Th1 cytokines decrease the expression of differentia-
tion proteins such as NIS, Tg, TPO, and DUOX (6,9–11,51,52).
FIG. 5. The effects of IL-4, NAC, and L-NAME on intra-
cellular ROS production in PCCL3 cells. The ROS signal was
measured in control cells (A) and cells exposed to IL-1a
(2 ng/mL) and IFNc (100 U/mL) (B); L-NAME (2.5 mM) (C);
IL-1a, IFNc, and L-NAME (D); IL-4 (2 ng/mL) (E); IL-1a,
IFNc, and IL-4 (F); NAC (1 mM) (G); IL-1a, IFNc, and NAC
(H). Scale bar: 10lm. L-NAME, N-nitroso-L-arginine methyl
ester; NAC, N-acetylcysteine.
FIG. 6. Quantification of ROS production in PCCL3 (A)
and human cells (B). The ROS signal assessed as DCFH-DA
fluorescence was quantified by measuring the mean fluo-
rescence of each cell. Data are expressed as fold changes vs.
controls and are represented as the mean – SEM of n= 10
repeats. *p< 0.05 vs. control. +p < 0.05 vs. IL-1a- and IFNc-
treated cells.
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Previous studies reported that the effects of Th1 cytokines on
the thyroid gland are partially mediated by RNS such as NO
(9,12,13), and we have previously demonstrated that Th1
cytokines may induce ROS production (11).
ROS are products of normal cell metabolism and can be
either harmful or harmless depending on their nature and the
amount produced (53). ROS include free radicals, including
O2
- , OH- , peroxyl (RO2
), alkoxyl (RO), and several non-
radical molecules such as H2O2. H2O2, which is produced by
DUOX at the apical pole of thyrocytes, is used by TPO as a
cofactor for iodide organification and coupling reactions (16–
18). ROS other than H2O2, such as OH
- and O2
- , are also
likely produced during TH synthesis, although in very small
amounts (22,54,55). Production of ROS is tightly controlled by
multiple potent intracellular antioxidants, including catalase,
superoxide dismutases, peroxiredoxins, and glutathione
peroxidases (17,56–61). In addition to their role in TH bio-
synthesis, ROS are also involved in controlled growth pro-
cesses such as those activated during goitrogenesis (62). As in
nonstimulated conditions (19), and in accordance with the
theory of redox homeostasis (53), the oxidative stress (OS) to
which growing thyrocytes are exposed is harmless, likely
because most of it is efficiently detoxified by the well-adapted
antioxidant defenses (56,62). In pathological situations, in-
cluding those simulated in models of iodine-induced thyroid
involution (11,22–26,63), a higher degree of OS occurs. This
intense OS originates from two sources, including the thyro-
cytes themselves and the numerous interstitial inflammatory
cells. Thus, while the natural antioxidant defenses are per-
fectly adapted to control the physiological intracellular ROS
load, they are unable to overcome the massive ROS attack
originating from interstitial cells (11). The intense OS that
occurs in animals predisposed to autoimmune disorders, such
as nonobese diabetic mice, may represent an early stage of
chronic thyroiditis (11).
One aim of this study was to get further insights into the
nature of ROS produced in cells incubated with Th1 cyto-
kines. We hypothesized that these ROS are unlikely to cor-
respond to H2O2 produced by DUOX for two reasons. First,
the tightly controlled production of H2O2 is restricted to a
specific area located in cell microvilli sometimes called the
thyroxisome by some authors. At this site, H2O2 is consumed
during the process of TH biosynthesis and any leakage of
intracellular H2O2 is readily detoxified (16–18). Second, sev-
eral studies have shown that expression levels of DUOX
mRNA and protein are downregulated in thyroid cells ex-
posed to Th1 cytokines, which suggests that H2O2 produced
at the interface with the colloid is not involved in Th1
cytokine–induced pathological effects (9–11). The lack of in-
volvement of extracellular H2O2 was confirmed here as the
exposure of thyroid cells to IL-1a and IFNc increased the
production of intracellular ROS, but decreased at the same
time the production of extracellular H2O2. EPR-based exam-
ination of ROS other than H2O2 indicated that OH
 is likely
not involved in the response to Th1 cytokines. This is not
really surprising considering the high reactivity of this toxic
radical. Indeed, OH reacts with almost all species it collides
with and subsequently generates even more toxic free radicals
(64). Conversely, it sounds reasonable to propose O2
- as
possible candidate among other ROS. This hypothesis is
supported in part by the DCFH-DA results, even though it is
known that the DCFH-DA probe cannot discriminate finely
between oxidants (65). One must admit that this hypothesis is
indirect as it is based on the observed increase in NOX2
mRNA expression in PCCL3 cells and in NOX2 protein ex-
pression in tissue samples of HT patients. To our knowledge,
it is the first time that an increase in NOX2 mRNA expression
in response to Th1 cytokines is reported in thyroid epithelial
cells and that a difference in NOX2 protein expression is re-
ported in HT patients compared with nonautoimmune con-
trols. NOX2 is known to be induced in many cell types,
including phagocytes exposed to IFN-c, myofibroblasts un-
dergoing carotid artery injury, cardiomyocytes undergoing
acute myocardial infarction, and adipose tissue, aorta, heart,
resistance artery vascular smooth muscle cells, and pancreatic
islets in response to angiotensin II (43,53). Bearing in mind
that NOX2 produces large amounts of O2
 - in various cell
models (activated macrophages and neutrophils, vascular
smooth muscle cells) (53), it makes sense to propose that O2
 -
is also produced in thyroid cells in response to Th1 cytokines.
As O2
 - can be readily converted into H2O2, either by spon-
taneous reduction or by dismutation (53,64), it is also possible
that intracellular H2O2, as opposed to extracellular H2O2
produced at the interface with the colloid, is part of ROS
produced in thyroid cells exposed to Th1 cytokines. As a re-
sult of the rapid reaction between O2
- and NO (53,65),
ONOO - could also be an additional candidate, but of course
this remains hypothetical and needs obviously to be further
explored.
In contrast to NOX2, NOX4 mRNA expression was not
affected by Th1 cytokines in this study. We looked at NOX4
because it is constitutively active in the nucleus and in the
endoplasmic reticulum of thyroid cells (43), where it is upre-
gulated during the estrous phase in female rats (66), as it is in
thyroid carcinomas (67).
There are at least three ways to partially or totally inhibit
the effects of Th1 cytokines on TPO and DUOX mRNA and
protein expression, as well as on Tg secretion: (i) incubation of
cells with increasing concentrations of TSH (9), (ii) co-
incubation of Th1 cytokine–challenged cells with L-NAME
(9), and (iii) co-incubation of cells with IL-4, a Th2 cytokine
(10). How the two last substances influence ROS production
was another question raised in this study. We show that when
Th1 cytokine–challenged thyroid cells are co-incubated with
either L-NAME or IL-4, there was a significant reduction in
intracellular ROS production close to that obtained with
NAC. Combined with data that have shown a marked or
almost complete restoration of TPO and DUOX protein and
mRNA expression in Th1 cytokine–treated cells incubated
with either L-NAME (9,14) or IL-4 (10), there are strong ar-
guments to claim that ROS/RNS act as intracellular mediators
of Th1 cytokine–induced effects in the thyroid. However,
ROS/RNS cannot be involved alone in this paradigm for at
least two reasons. First, although L-NAME decreases ROS
production close to that seen in NAC-treated cells, the thyroid
cell function is restored, but only partially (9). Second, even
though NAC fully blocks ROS production in Th1 cytokine–
treated thyroid cells, TPO and DUOX expression is not only
unrecovered, but even further repressed (11), suggesting that,
in addition to ROS/RNS, other factors must play a role in the
regulation of thyroid cells exposed to Th1 cytokines (see Fig.
7). This hypothesis opens future research perspectives, for
instance, addressing the nature of intracellular pathways ac-
tivated in response to IL-4 and how, beyond the blockage of
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ROS/RNS production, these pathways control Th1 cytokine–
induced effects. Although this research is outside the scope of
the present study, we do propose that the Janus kinase ( JAK)
and signal transducer and activator of transcription (STAT)
pathway could be one of those. This proposal is supported by
a recent article that described an activation of the JAK1-STAT6
cascade, a rapid induction of DUOX2/DUOXA2, and a sig-
nificant increase in calcium-stimulated extracellular H2O2
production in human thyroid cells treated with IL-4 (33).
These observations may otherwise explain the moderate and
harmless increase in the oxidative load by IL-4 observed in the
present study.
In conclusion, this study reinforces the concept that ROS
and RNS play a role in Th1 cytokine–induced alterations of
thyroid cell function. Intracellular production of ROS and RNS
may result from the activation of NOS/NOX enzyme complexes;
DUOX being concomitantly repressed. Although ROS and RNS
are important, they are unlikely to be the sole mediators of the
inhibitory effects of Th1 cytokines on thyroid function and ad-
ditional intracellular pathways may also play a role (Fig. 7).
FIG. 7. Schematic representation of the role of ROS and RNS as important, but not exclusive, intracellular mediators of Th1
cytokine–induced effects in thyroid epithelial cells. (A) Under normal conditions, a redox homeostasis is maintained in the
cell as the result of balanced ROS production and clearance by scavenging mechanisms. TPO and DUOX are involved in
biosynthesis of TH at a restricted area of the cell sometimes called the thyroxisome (16–18), at which extracellular H2O2 is
produced and used directly by TPO. Light gray coloring represents the redox homeostasis. (B) When thyroid epithelial cells
are exposed to IL-1a and IFNc (Th1 cytokines), there is an immediate and robust increase in intracellular ROS/RNS pro-
duction. The nature and source of these ROS are still unclear, but this study has confirmed that extracellular H2O2 produced
by DUOX is unlikely to be involved and that mitochondria are not the source. An alternative source of ROS production could
be NOX2 because its expression is significantly increased in thyroid cells incubated with IL-1a and IFNc, as well as in the
thyroid of HT patients. The results presented here indicate that NOX4 is not involved. Although the exact nature of the ROS
produced in Th1 cytokine–treated cells is still to be determined, the EPR experiment indicated that OH is not among the
species produced. A potential candidate could be O2
- because NOX2 is known to produce this oxygen species. As O2
- is
rapidly transformed into H2O2, we propose that intracellular H2O2 could be another potential source of ROS produced in
cells incubated with IL-1a and IFNc. As O2
- may combine with NO produced by NOS2 upon stimulation of cells with IL-1a
and IFNc, ONOO- could also be one of the ROS produced in response to Th1 cytokines. The antioxidant defenses (AntiOx)
(56) are potent enough to buffer the intracellular ROS attack and to avoid cell destruction (which is no more the case when
ROS attack is generated from outside epithelial cells as from infiltrating inflammatory cells). Other intracellular pathways
(dashed lines) are likely activated in response to Th1 cytokine exposure. They must still be explored. Dark gray coloring
represents the strong increase in oxidative stress in Th1 cytokine–treated cells. DUOX, dual oxidase; RNS, reactive nitrogen
species; TPO, thyroperoxidase.
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